| 1893- | dietMet, | Clinical Studies of Methionine-Restricted Diets for Cancer Patients |
| - | Review, | Var, | NA |
| 1897- | dietMet, | Methionine metabolism in health and cancer: a nexus of diet and precision medicine |
| - | Review, | Var, | NA |
| 1896- | dietMet, | Dietary methionine links nutrition and metabolism to the efficacy of cancer therapies |
| - | in-vivo, | CRC, | NA |
| 1895- | dietMet, | Altering Diet Enhances Response to Cancer Treatments in Mice |
| - | Review, | Var, | NA |
| 1894- | dietMet, | Long term methionine restriction: Influence on gut microbiome and metabolic characteristics |
| - | in-vivo, | Nor, | NA |
| 5188- | dietMet, | Dietary methionine links nutrition and metabolism to the efficacy of cancer therapies |
| - | in-vivo, | Var, | NA |
| 5193- | dietMet, | Rad, | A Phase I Trial of a Methionine Restricted Diet with Concurrent Radiation Therapy |
| - | Trial, | Var, | NA |
| 5192- | dietMet, | Intermittent methionine restriction reduces IGF‐1 levels and produces similar healthspan benefits to continuous methionine restriction |
| - | in-vivo, | Nor, | NA |
| 5191- | dietMet, | Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade |
| - | in-vitro, | Colon, | HT29 |
| 5190- | dietMet, | Methionine restriction activates the integrated stress response in triple-negative breast cancer cells by a GCN2- and PERK-independent mechanism |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 5189- | dietMet, | Mechanism of Activation of Mechanistic Target of Rapamycin Complex 1 by Methionine |
| - | Review, | Var, | NA |
| 2160- | dietP, | Dietary proteins and protein sources and risk of death: the Kuopio Ischaemic Heart Disease Risk Factor Study |
| - | Trial, | Heart, | NA |
| 2165- | dietP, | SFN, | Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects—results from the POUDER pilot study |
| - | Trial, | PC, | NA |
| 2163- | dietP, | SFN, | Intake of Cruciferous Vegetables Modifies Bladder Cancer Survival |
| - | Human, | Bladder, | NA |
| 2162- | dietP, | Effect of low-fat diet on breast cancer survival: a meta-analysis |
| - | Analysis, | BC, | NA |
| 2161- | dietP, | Plant-Based Diets and Cancer Prognosis: a Review of Recent Research |
| - | Review, | Var, | NA |
| 2159- | dietP, | Postdiagnostic Fruit and Vegetable Consumption and Breast Cancer Survival: Prospective Analyses in the Nurses' Health Studies |
| - | Human, | BC, | NA |
| 2158- | dietP, | Association of Animal and Plant Protein Intake With All-Cause and Cause-Specific Mortality in a Japanese Cohort |
| - | Human, | Nor, | NA |
| 2157- | dietP, | Plant-Based Diets and Disease Progression in Men With Prostate Cancer |
| - | Study, | Pca, | NA |
| 2156- | dietP, | Phytochemical-rich vegetable and fruit juice alleviates oral mucositis during concurrent chemoradiotherapy in patients with locally advanced head and neck cancer |
| - | Human, | HNSCC, | NA |
| 2155- | dietP, | Transepithelial Anti-Neuroblastoma Response to Kale among Four Vegetable Juices Using In Vitro Model Co-Culture System |
| - | in-vivo, | neuroblastoma, | Caco-2 | - | NA, | NA, | SH-SY5Y |
| - | Trial, | Colon, | NA |
| 5065- | dietSTF, | dietFMD, | Nutrition, GH/IGF-I Signaling, and Cancer |
| - | Review, | Var, | NA |
| 5066- | dietSTF, | Intermittent and Periodic Fasting, Hormones, and Cancer Prevention |
| - | Review, | Var, | NA |
| 5068- | dietSTF, | mTOR-autophagy axis regulation by intermittent fasting promotes skeletal muscle growth and differentiation |
| - | in-vivo, | Nor, | NA |
| 5069- | dietSTF, | The Role of Intermittent Fasting in the Activation of Autophagy Processes in the Context of Cancer Diseases |
| - | Review, | Var, | NA |
| 5070- | dietSTF, | A review of fasting effects on the response of cancer to chemotherapy |
| - | Review, | Var, | NA |
| 5071- | dietSTF, | Unraveling the impact of intermittent fasting in cancer prevention, mitigation, and treatment: A narrative review |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4180- | dietSTF, | Brain-derived neurotrophic factor, but not body weight, correlated with a reduction in depression scale scores in men with metabolic syndrome: a prospective weight-reduction study |
| - | Human, | Obesity, | NA |
| 4159- | dietSTF, | 2DG, | CRMs, | Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms |
| - | Review, | AD, | NA |
| 3707- | dietSTF, | Intermittent fasting protects against the deterioration of cognitive function, energy metabolism and dyslipidemia in Alzheimer’s disease-induced estrogen deficient rats |
| - | in-vivo, | AD, | NA |
| 3708- | dietSTF, | Fasting as a Therapy in Neurological Disease |
| - | Review, | Nor, | NA |
| 3709- | dietSTF, | Intermittent Fasting Protects against Alzheimer’s Disease Possible through Restoring Aquaporin-4 Polarity |
| - | in-vitro, | AD, | NA |
| 1626- | dietSTF, | dietFMD, | When less may be more: calorie restriction and response to cancer therapy |
| - | Review, | Var, | NA |
| 8840- | DIM, | Inactivation of uPA and its receptor uPAR by 3, 3'-Diindolylmethane (DIM) leads to the inhibition of Prostate Cancer Cell growth and migration |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B | - | in-vitro, | Pca, | PC3 |
| 8857- | DIM, | Induction of G1 and G2/M cell cycle arrests by the dietary compound 3,3'-diindolylmethane in HT-29 human colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 8839- | DIM, | 3,3'-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression |
| - | in-vitro, | BC, | MDA-MB-231 |
| 8838- | DIM, | 3,3'-Diindolylmethane induces a G(1) arrest in human prostate cancer cells irrespective of androgen receptor and p53 status |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 8837- | DIM, | 3,3'-Diindolylmethane is a novel mitochondrial H(+)-ATP synthase inhibitor that can induce p21(Cip1/Waf1) expression by induction of oxidative stress in human breast cancer cells |
| - | in-vitro, | BC, | MCF7 |
| 8836- | DIM, | Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane |
| - | vitro+vivo, | BC, | MCF7 |
| - | Trial, | Cerv, | NA |
| 8834- | DIM, | Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial |
| - | Trial, | Cerv, | NA |
| 8826- | DIM, | Single-Dose Pharmacokinetics and Tolerability of Absorption-Enhanced 3, 3′-Diindolylmethane in Healthy Subjects |
| - | Study, | Nor, | NA |
| 8827- | DIM, | Inhibition of breast cancer cell growth and induction of cell death by 1,1-bis(3'-indolyl)methane (DIM) and 5,5'-dibromoDIM |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 8828- | DIM, | Induction of growth arrest and apoptosis in human breast cancer cells by 3,3-diindolylmethane is associated with induction and nuclear localization of p27kip |
| - | in-vitro, | BC, | MCF-10AT | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | BT20 | - | in-vitro, | BC, | BT474 |
| 8829- | DIM, | Anti-androgenic activity of absorption-enhanced 3, 3’-diindolylmethane in prostatectomy patients |
| - | Human, | Pca, | NA |
| 8830- | DIM, | Tam, | A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen |
| - | Trial, | BC, | NA |
| 8831- | DIM, | 3,3′-Diindolylmethane Exhibits Significant Metabolism after Oral Dosing in Humans |
| - | Human, | Nor, | NA |
| 8832- | DIM, | Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy |
| - | Trial, | Pca, | NA |
| 8833- | DIM, | A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer |
| - | Trial, | Pca, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid